Human T-cell leukemia virus type 1 (HTLV-1), which causes adult T-cell leukemia (ATL) in humans, establishes a life-long latent infection. Current therapies are not very effective against HTLV-1-associated disorders. A novel therapeutic approach may help to combat HTLV-1 infection. A molecular therapy that targets the proviral genome is favorable because the therapeutic effect occurs specifically in HTLV-1-infected cells, regardless of whether they express viral genes. In this proof-of-concept study, we developed a therapeutic molecule based on zinc finger nuclease (ZFN) to achieve this goal. We designed a ZFN that specifically recognized conserved region of HTLV-1 long terminal repeat (LTR) and introduced it into various HTLV-1-positive human T-cell lines, including HTLV-1-transformed and ATL-derived cell lines. The ZFN disrupted the promoter function of HTLV-1 LTR and specifically killed HTLV-1-infected cells. We also showed a potential approach of this therapeutic molecule to remove the proviral genome from HTLV-1-infected cells, something that has not been possible before. The therapeutic effect of ZFN was confirmed in an in vivo model of ATL. This strategy may form the basis of a therapy that can eradicate HTLV-1 infection. Similar approaches can be used to target other malignancy-associated viruses.
INTRODUCTION
Human T-cell leukemia virus type I (HTLV-1) is a retrovirus that causes adult T-cell leukemia (ATL) and the neurological disorder, HTLV-1-associated myelopathy, in humans. [1] [2] [3] HTLV-1 establishes a life-long latent infection because the viral genome is integrated into the host cell DNA. HTLV-1 undergoes the lytic phase of the viral life cycle in some infected cells, whereas most of the other cells remain latently infected. Once the viral genes are expressed, the host immune system can remove infected cells; however, it is difficult to eradicate HTLV-1-positive cells completely from infected individuals because latently infected cells do not actively transcribe the viral genes. No cell surface markers have been identified that distinguish HTLV-1-infected cells from uninfected cells. No effective vaccine has yet been developed, and HTLV-1-associated disorders respond poorly to current therapies. 4, 5 Thus, a molecular therapy is urgently needed. Considering the phenomenon of viral latency, it is reasonable to target the provirus. Here, we used artificial endonuclease technology to achieve this goal.
Zinc finger nuclease (ZFN), a synthetic endonuclease, introduces a double strand break (DSB) into its cognate DNA site, thereby activating DNA damage-induced apoptosis.
6-8 Therefore, we hypothesized that targeting the HTLV-1 provirus with ZFN should kill HTLV-1-infected cells by DSB-induced apoptosis, resulting in the elimination of provirus-positive cells from the virus-infected individuals (Supplementary information S1). Some of the DNA strand break sites are repaired by DNA damageresponse mechanisms such as non-homologous end joining, which ligates the broken ends of the chromosomal DNA. When this occurs, the original DNA sequence is disrupted. The integrated retroviral genome has two identical copies of a sequence known as the viral long terminal repeat (LTR). Targeting the LTR is advantageous because the number of therapeutic targets per provirus is doubled (no other part of the viral genome has two copies). The LTR acts as a viral promoter; therefore, even if cell death is not induced, the proviral DNA should be irreversibly damaged, thereby reducing expression of the viral genes and subsequent pathogenicity. Furthermore, ZFN removes a DNA fragment from the chromosome.
1 This is possible when two DSBs are introduced into the chromosomal DNA proximal to each other. The DSB repair system ligates the DNA ends and removes the short DNA fragment generated by the two DSBs (a process termed as targeted deletion activity; Supplementary information S1). Thus, it should be possible to delete the proviral gene if a repetitive element, such as the LTR, which is positioned at either ends of the provirus, is targeted by ZFN. Therefore, we conducted a proof-ofconcept study in which we used ZFN to damage the HTLV-1 provirus in infected cells and inhibit cell proliferation of virusinfected cells. It was possible to design a ZFN molecule with the required properties because the endonuclease has high-substrate specificity, and the HTLV-1 LTR has limited sequence diversity compared with the LTR of human immunodeficiency virus.
MATERIALS AND METHODS

Cells and transfection
All T-cell lines were maintained in RPMI 1640 (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (Japan Bioserum, Tokyo, Japan), penicillin and streptomycin (Invitrogen, Tokyo, Japan). Dulbecco's modified eagle medium (Sigma) was used to culture the 293 T cells. Cells were incubated at 37 1C in a humidified atmosphere containing 5% CO 2 . Cells were transfected using Lipofectamine 2000 (Invitrogen) or FuGENE6 transfection reagents (Roche, Tokyo, Japan). The S1T and ED cell lines were generous gifts from Drs Baba (Kagoshima University) and Matsuoka (Kyoto University).
Plasmids and the murine leukemia virus vector ZFN genes were purchased from Sigma. The retroviral plasmids pQc, pCMMP and pMX were constructed using standard molecular cloning techniques. The Tax-expressing plasmid, pCGtax, and pHTLV LTR-luciferase are kindly provided by Dr Watanabe (Tokyo University). The production of, and infection by, murine leukemia virus (MLV) vectors has been described previously. [9] [10] [11] Cell imaging Cells were imaged by confocal fluorescence microscopy (LSM510 Meta Â 40 NA 1.4 lens, Carl Zeiss MicroImaging Inc., Tokyo, Japan) or fluorecence microscopy (Olympus IX70, Tokyo, Japan). (20, 100 or 500 ng; containing each subunit alone or an equal amount of each subunit (1/2 or 3/4), Tax (100 ng) and a reporter plasmid encoding the LTR-luciferase cassette (200 ng) were cotransfected into 293 T cells, and the luciferase signals were detected at 2 days post transfection (red). The expression vector containing GFP was used as the control. The total amount of transfected plasmid was adjusted using a plasmid-expressing GFP. A CMV-driven luciferase expression vector (50 ng) was used for comparison (blue). The average and standard deviation of the luciferase signals relative to that of the control is shown from four independent experiments. Statistically significant differences between each plasmid and the corresponding CMV control were analyzed using a two-tailed Student's t-test (asterisk denotes Po0.01). Number of bacterial colonies emerged on a 10-cm Luria-Bertani agar plate containing x-Gal.
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Reporter assay
Luciferase activity was measured 48 h after transfection or infection using a Dual-Glo or Renilla-Glo Luciferase assay kit (Promega, Madison, WI, USA) according to the manufacturer's protocol. Chemiluminescence was detected with a Veritas luminometer (Promega).
Immunoblotting
Western blotting and immunoprecipitation were performed as previously described 12 using an anti-FLAG antibody (F7425, Sigma) and Envision Dual Link System-HRP (Dako, Glostrup, Denmark). Chemiluminescence was generated using Lumilight (Roche) or Lumigen (GE Healthcare, Tokyo, Japan), and the signals were detected using an LAS-3000 mini Lumino-Image analyzer.
Cell proliferation assay C8166 and S1T cells were transduced with ZFN genes inserted into the MLV vector and bulk-selected in medium containing 1 mg/ml puromycin. The cells were then transduced with a second ZFN gene in the MLV vector, seeded into 96-well plates (5 or 100 cells/well), and selected in medium containing 500 mg/ml G418 at 3 days post infection. The number of wells containing viable cells was counted at 3-4 weeks post selection. Cellular DNA was isolated using the Wizard DNA Purification Kit (Promega), and the proviral DNA sequence was analyzed by sequencing after PCR amplification of the target regions.
Mouse study Balb/c nude Rag-2/Jak3 double-deficient (nude R/J) mice were established by crossing Balb/c nude mice and Balb/c Rag-2/jak3 double-deficient mice. 13 Nude R/J mice were inoculated subcutaneously in the right and left flanks with 2 Â 10 5 ED ZFN2/ZFN1 and ED ZFN2/ZFN2 cells, respectively. Tumor growth was monitored at 6 weeks post inoculation by weekly measurement of the maximal and minimal diameter using calipers. Tumor size was estimated using the formula: tumor size (mm 3 ) ¼ length (mm) Â width 2 (mm) Â 0.4. 14,15 The mice were housed and monitored in the animal research facility according to institutional guidelines. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee at Kumamoto University (B23-201).
Statistical analysis
Experimental results were analyzed by Student's t-test, Person's exact test or Paired Wilcoxon Rank-Sum test, as appropriate. Po0.05 were considered statistically significant.
RESULTS
We synthesized two pairs of ZFNs that targeted the HTLV-1 LTR, which are: ZFN1/2, which recognizes the R region (524-563 bp, according to the GenBank accession number D13784 coordinate) and ZFN3/4, which recognizes the U5 region (627-665 bp) ( Figure 1a ). According to our own data and the NCBI database, these sequences are conserved in 77.8% (14/18 clones) of independent HTLV-1 clones isolated in Asia, Europe, and North and South America. Sequence analysis indicated that the human genome does not contain sequences that are identical to these ZFN targets. ZFN was tagged at the N-terminus with a 3 Â FLAG epitope and ZFN expression was verified by western blotting of 293 T cells transfected with the ZFN expression vectors (Figure 1b) . As the ZFNs were fused to a nuclear localization signal, they were distributed predominantly in the nucleus (Figure 1c) .
Next, ZFN activity was examined in human cells. First, we assessed whether ZFN inhibited LTR-driven gene expression. For this purpose, ZFN expression vectors were transfected into 293 T cells along with a Tax expression vector and a reporter plasmid encoding an HTLV-1 LTR-luciferase cassette. Luciferase activity was markedly reduced upon coexpression of functional ZFN pairs (Figure 1d ). This effect was dependent upon the amount of plasmid transfected. By contrast, ZFN expression did not affect the transcriptional activity of the cytomegalovirus (CMV) promoter (Figure 1d) . Second, two deletion reporter plasmids were constructed to test the targeted deletion activity. One deletion reporter harbored a CMV promoter and green fluorescent protein (GFP) and renilla luciferase genes (Figure 2a) . The GFP gene was sandwiched by the cognate ZFN site (Figure 2a) . The renilla luciferase was not expressed unless the GFP cassette was removed. The results of a cotransfection experiment in 293 T cells showed that GFP fluorescence decreased substantially in the presence of functional ZFN subunits (Figure 2b) , whereas a marked increase in renilla luciferase activity was detected upon coexpression of functional ZFN subunits (Figure 2c ).
To confirm this finding, we constructed another deletion reporter containing a bacterial LacZ-alpha expression cassette flanked by ZFN cognate sites and cotransfected it into 293 T cells with the ZFN expression plasmids. Escherichia coli were then transformed with DNA recovered from the transfected 293 T cells. Deletion of the LacZ-alpha expression cassette should result in white bacterial colonies on agar plates containing X-Gal. As expected, the number of white colonies increased substantially when the ZFN pairs were expressed in 293 T cells (Table 1) . Interestingly, expression of the ZFN pairs caused a reduction in the number of colonies, suggesting that DSBs were efficiently introduced into the reporter plasmid, but not all of the DSB loci were ligated by the DSB repair system in 293 T 
Abbreviations: HTLV-1, human T-cell leukemia virus type 1; ZFN, zinc finger nuclease. Table 3 . Detection of ZFN-mediated site-directed mutagenesis in S1T cells.
ZFN a
No. of clones examined
No. of clones with site-specific mutation
Abbreviation: ZFN, zinc finger nuclease. a The order of transduction into cells is indicated.
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A Tanaka et al cells. A small number of white colonies were observed, presumably because ZFN-independent deletion of LacZ from the reporter plasmid occurs spontaneously and with low frequency. Taken together, these data suggest that ZFNs inhibit the function of the LTR promoter and remove DNA flanked by the ZFN cognate sites. We assume that the inhibition of LTR promoter function (Figure 1d ) was caused by physical damage to the LTR. We next examined the biological effect(s) of ZFNs in HTLV-1-transformed and ATL-derived CD4-positive human T-cell lines, harboring the HTLV-1 provirus. HTLV-1 immortalizes human CD4-positive T cells, and the proliferation of HTLV-1-transformed cells is dependent on HTLV-1 gene expression. If ZFN inhibits the promoter function of the LTR, then ZFN expression should inhibit the proliferation of HTLV-1-transformed cell lines. In addition, HTLV-1-positive cells should undergo DSB-triggered apoptosis upon ZFN expression. We confirmed that the ZFN target sequence in the LTR was conserved in all the cell lines used in this study. Initially, we transduced a subunit of ZFN into C8166 cells 16 using a MLV vector. A second ZFN subunit was then transduced into the cells using a MLV vector carrying a distinct selection marker, and cell proliferation was examined by measuring the cell-cloning efficiency (Figure 3a) . For the control cells, the same ZFN subunit that was transduced initially was introduced again (referred to as a "non-functional pair"). When the functional ZFN1/2 and ZFN3/4 pairs were expressed, the cloning efficiency of C8166 cells was significantly reduced by 26.9-and 20.0-fold, respectively, compared with that of the control (P ¼ 0.001 and P ¼ 0.002, respectively; Student's t-test, Table 2 ). Next, we examined the ATL cell line S1T, which proliferates in an interleukin-2-independent manner. 17 Under the same experimental conditions, the cloning efficiency of S1T cells was reduced by 4.4-and 1.9-fold compared with the control when functional ZFN1/2 and ZFN3/4 pairs, respectively, were expressed ( Table 2 ). The reduction in the cellcloning efficiency mediated by ZFN1/2 (but not ZFN3/4) was statistically significant (Po0.001; Student's t-test). Proliferative inhibition of HTLV-1-transformed and ATL-derived cell lines was observed when cell growth was assessed in bulk culture using metabolic measurements (data not shown). We observed similar results in HTLV-1-transformed MT-2 and MT-4 cells, and the ATLderived cell lines, ED and TL-OmI (data not shown). Furthermore, these findings were not observed in four HTLV-1-negative CD4-positive T-cell lines, including CEM, MOLT-4, Jurkat and SUP-T1 (data not shown). These data suggest that ZFN inhibits the proliferation of HTLV-1-infected cells, specifically. We also noted that the cell-cloning efficiency was reduced to a greater extent in HTLV-1-transformed cells than in ATL-derived cells. Presumably, this is because HTLV-1-transformed cells are more susceptible to DSB-induced apoptosis.
Next, the physical damage to the LTR sequence caused by ZFN was examined in S1T cell clones recovered from the above experiment. We identified site-specific mutations in 44.1% (15/34 clones) of LTR sequences derived from S1T cell clones, expressing functional ZFN pairs, whereas no mutations were found in LTR clones isolated from the controls (0/7 clones, Po0.05; Pearson's exact test, Table 3 ). Most of the mutations were deletions (average, 14.1 bp/clone). Expression of ZFN3/4 resulted in larger deletions (15.0 bp/clone) than expression of ZFN1/2 (10.2 bp/clone). An insertional mutation was detected only in a single ZFN3/4-transduced clone (2 bp, 2.9%, 1/34 clones; Figures  3b and c) . These data suggest that DSB repair occurs in ATL cells, but that the quality of the repair at the ZFN1/2 and ZFN3/4 sites is different. We assume that clones bearing a wild-type LTR might have failed to express ZFNs efficiently, or lost ZFN expression during selection.
The promoter activity of some LTR mutants was examined in a reporter assay in which the reporter plasmid contained both firefly and renilla luciferases, representing positive and negative strand transcription, respectively (Figure 3d-g ). The Tax-augmented transcription of the positive strand was reduced by most of the mutations introduced by ZFN1/2 (4/6 clones, Figure 3d) . Similarly, the negative strand transcription was also reduced by ZFN1/2-induced mutations (5/6 clones, Figure 3e ). On the other hand, increased positive strand transcription was observed in 4/7 LTR mutants recovered from ZFN3/4-transduced cells (Figure 3f ).
By contrast, many of the LTR mutants showed modestly reduced negative strand transcription (Figure 3g ). Sequence analysis suggested that the LTR sequences targeted by ZFNs do not contain binding sites for previously-known transcription factors; therefore, it is possible that the ZFN1/2 target site spans a cis-acting element that supports the efficient transcription of the positive strand. All S1T cell clones were positive for the gag gene, suggesting that removal of the entire proviral genome was inefficient, or that ATL cells cannot proliferate without the provirus. However, some S1T cell clones showed reduced gagto-LTR ratios as measured by quantitative real-time PCR, suggesting that removal of some proviral gene copies is possible (data not shown). Taken together, these data suggest that ZFN-mediated killing of S1T cells is not because of the loss of viral genes, but more likely due to DSB-induced apoptosis.
To evaluate the potential of ZFN1/2 to inhibit tumorigenicity of ATL cells in vivo, we adopted ATL cell xenograft model in Balb/c nude Rag-2/Jak3 double-deficient (nude R/J) mice. We chose to use ED cells because they form a tumor mass in nude mice and do not require human interleukin-2 for growth. 18 In addition, ED cells are highly susceptible to infection by MLV vectors. As shown above, the biological effect of ZFN1/2 was greater than that of ZFN3/4 in both HTLV-1-transformed and ATL-derived cell lines. Therefore, we used the ZFN1/2 pair for the in vivo study. ED cells constitutively expressing ZFN2 (ED ZFN2 ) were infected with MLV vectors, harboring GFP, ZFN1 or ZFN2 gene (Figure 3a) . Approximately half of the cells were infected by the MLV vectors as estimated by the number of GFP-positive cells (data not shown). Cells were inoculated intradermally into into nude mice at 2 days post-MLV infection. ED ZFN2/ZFN1 cells showed a lower rate of tumor formation, and the tumors were significantly smaller than those in control mice (Paired Wilcoxon Rank-Sum test, Po0.05; Figure 4 ). These data indicate that ZFN1/2 shows promising therapeutic efficacy against ATL.
DISCUSSION
We synthesized two pairs of ZFNs that successfully targeted the HTLV-1 proviral LTR and inhibited the proliferation of HTLV-1-transformed and ATL-derived T-cell lines. ZFN caused physical damage to the LTR and disrupted its function. Even though some cells survived, they contained a defective provirus; therefore, the therapeutic effects should be long-lasting. ZFN was able to remove at least a part of proviral genes from HTLV-1-infected cells and showed anti-tumor effects in vivo. Taken together, these data show that ZFN is an attractive therapeutic molecule for treating HTLV-1 infection, and may form the basis of a treatment that eliminates the virus from infected cells. Previous studies used ZFN to edit the human genome. 19, 20 However, the work reported herein is unique in that ZFN was used to kill target cells via DSB-triggered apoptosis. This approach can be used for other viruses that establish latent infections and are associated with human malignancies, including retroviruses, EpsteinBarr virus, Kaposi sarcoma herpes virus, papilloma virus and hepatitis B virus.
The choice of a viral vector may improve the efficacy of ZFN in terms of limiting the proliferation of HTLV-1-infected cells. We delivered the ZFN gene using an MLV vector; however, adenoviral vectors have been used for the clinical application of ZFNs. 20 The advantage of an adenoviral vector is that it induces transient, but high levels of ZFN expression, whereas retroviral vectors express the gene of interest constitutively, but at low levels. We found that ZFN expression in cells gradually decreased after the long-term cultivation, as is often the case with other genes. This suggests that MLV-mediated gene transduction may not be appropriate for clinical application. We also expect that ZFN-mediated cell killing can be enhanced by inhibiting DSB repair proteins, a method used to increase the efficacy of DNA-damaging agents against tumor cells.
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The major hurdle that must be overcome if ZFNs are to be used clinically to treat HTLV-1 infection is their efficient delivery to virus reservoirs. To eliminate HTLV-1 from infected individuals, ZFN must be delivered directly to latently infected cells; however, the latent reservoir of HTLV-1 is poorly understood. Although ZFN has a high-substrate specificity and its non-specific effects are thought to be minimal, delivery of ZFN to all the cells may not be desirable. Cell surface markers of HTLV-1-infected cells, either transformed or not, remain to be identified. We must increase our understanding of HTLV-1 latency if we are to use ZFNs in a clinical setting. Offtarget effects are another concern. Although ZFN did not inhibit the proliferation of HTLV-1-negative cells, the risk that ZFNs may edit the human genome must be addressed in future studies. Phase I and II clinical trials using ZFN to treat human immunodeficiency virus infection and recurrent/refractory malignant glioma are currently underway (NCT00842634, 01044654, and 01082926), suggesting that the clinical application of ZFN is feasible. Another issue to be addressed is the stage of HTLV-1 infection at which ZFN should be used; for example, during the latent period or after the onset of HTLV-1-associated disease.
